Click here to learn more about

THE ONLY IG WITH TWO NEUROMUSCULAR INDICATIONS

US-GGL-0670v1.0 07/24

GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as a replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older, as maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN). Click here to learn more about an additional neuromuscular indication.

GAMMAGARD LIQUID Vial Sizes and Storage

Greater flexibility with the potential for less waste

GAMMAGARD LIQUID is offered in a broad range of vial sizes: 1 g (10 mL), 2.5 g (25 mL), 5 g (50 mL), 10 g (100 mL), 20 g (200 mL), and 30 g (300 mL). With 6 options, you have greater flexibility and potential to reduce product waste.1

How many grams are you potentially wasting?

Select average number of patients on intravenous immune globulin (IVIG) in your practice

  • 10
  • 20
  • 30
  • 40
  • 50
  • 60
  • 70
  • 80
  • 90
  • 100

If you are using an IVIG product with minimum dose of 5 g every 4 weeks, you could be wasting approximately:

Monthly

0 g

Yearly

0 g

Convenient vial sizes1

Size Grams Protein NDC
10 mL 1 g 0944-2700-02
25 mL 2.5 g 0944-2700-03
50 mL 5 g 0944-2700-04
100 mL 10 g 0944-2700-05
200 mL 20 g 0944-2700-06
300 mL 30 g 0944-2700-07

Latex content in packaging

  • The packaging is not made with natural rubber latex

Shelf life/storage requirements

  • Up to 36 months at refrigerated temperature from the date of manufacture: 2°C-8°C (36°F-46°F)
  • Up to 24 months at room temperature from the date of manufacture: not to exceed 25°C (77°F)
  • Do not use past expiration date printed on label
  • Do not freeze

Designed for ease of use

  • Using a 30 g vial may help reduce the number of vials required and reduce the need for handling.2
  • In a retrospective analysis of IVIG pharmacy claims (n=1,349)*
    • 55% of patients received a dose of 30 g or higher2
    • 30 g was the most frequently prescribed dose (nearly 1 in 5)2
    • For patients receiving greater than 30 g, with a 30 g vial:*
      • 47% reduction in the number of vials needed2
      • 97% of all prescriptions dispensed with 3 or fewer vials2†

*Based on a 2010 analysis of 1,354 patients with PI presenting 11,620 dispensing records

Compared with 70% of prescriptions dispensed prior to the introduction of the 30 g vial

Patient talking to his doctor.
Primary immunodeficiency icon.

Review details for GAMMAGARD LIQUID specific to PI

PI information
Multifocal motor neuropathy icon.

Review details for GAMMAGARD LIQUID specific to MMN

MMN information